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Abstract 
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are shown to participate in tumor 
progression by establishing a favorable tumor microenvironment (TME) that promote metastasis 
through a cytokine networks. However, the mechanism of homing and recruitment of BM-MSCs into 
tumors and their potential role in malignant tissue progression is poorly understood and controversial. 
Here we show that BM-MSCs increase aggressiveness of triple-negative breast cancer (TNBC) cell lines 
evaluated as capability to migrate, invade and acquire stemness markers. Importantly, we demonstrate 
that the treatment of BM-MSCs with a nuclease-resistant RNA aptamer against platelet-derived growth 
factor receptor β (PDGFRβ) causes the inhibition of receptor-dependent signaling pathways thus 
drastically hampering BM-MSC recruitment towards TNBC cell lines and BM-MSCs trans-differentiation 
into carcinoma-associated fibroblast (CAF)-like cells. Moreover, in vivo molecular imaging analysis 
demonstrated the aptamer ability to prevent BM-MSCs homing to TNBC xenografts. Collectively, our 
results indicate the anti-PDGFRβ aptamer as a novel therapeutic tool to interfere with BM-MSCs 
attraction to TNBC providing the rationale to further explore the aptamer in more complex pre-clinical 
settings. 
Key words: Bone marrow-derived mesenchymal stem cells, aptamer, platelet-derived growth factor receptor β, 
triple-negative breast cancer. 
Introduction 
Mesenchymal stem cells (MSCs) are multi-potent 
cells that in response to a large variety of bioactive 
molecules, growth factors, cytokines and chemokines, 
are recruited to injured or inflamed tissue to support 
their repair contributing to stem cells homeostasis and 
immunomodulation [1]. Similar to site of injury, 
tumors through production of paracrine and 
endocrine signals enrolled MSCs in their 
microenvironment (TME) that is seen as a "wound 
that never heals" [2]. The ability of MSCs to migrate to 
tumors makes them potential cargo for anticancer 
agents [3]. Once reached the tumors, MSCs may exert 
opposite roles depending on tumor types, thus 
supporting cancer progression, as reported in breast 
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[2], melanoma [4], prostate [5] and colon [6] 
carcinomas or suppressing it, as in malignant glioma 
[7]. The main source of MSCs in adult is bone marrow, 
even if additional tissues have been identified as font 
[8]. Bone marrow-derived mesenchymal stem cells 
(BM-MSCs) along with fibroblasts, pericytes, 
adipocytes, macrophages and immune cells play a 
crucial role into microenvironment of breast cancers, 
promoting extracellular matrix remodeling, cell 
migration and invasion, neo-angiogenesis, drug 
resistance and evasion of immunosurveillance [9, 10]. 
Once in TME, BM-MSCs can trans-differentiate into 
cancer-associated fibroblasts (CAFs), tumor- 
associated macrophages (TAMs) or vascular and 
perivascular cells switching from neutral role toward 
pro-tumorigenic behavior [11]. Recently, we reported 
the ability of BM-MSCs to promote migration, 
invasion and epithelial-mesenchymal transition 
(EMT) of osteosarcoma and hepatocellular carcinoma 
cells through chemokine receptor type 4 (CXCR4) [12]. 
In the last decade, different biomolecules have been 
found involved in BM-MSCs recruitment and activity 
into breast cancer including chemokine C-C motif 
ligand 5 (CCL5) [2]; transforming growth factor β 
(TGF-β) and interleukin 17B [13]; CXCL10 and 
placental growth factor [14]. Recently, it has been 
reported that platelet-derived growth factor receptor 
β (PDGFRβ) signaling plays an important role in 
recruitment of MSCs towards tumor sites [15]. In 
addition, Dhawan et al. [16] showed that 
platelet-derived growth factor BB (PDGF-BB) along 
with basic fibroblast growth factor (bFGF) are 
involved in bone marrow support in the 
dissemination of breast cancer cells.  
Triple-negative breast cancers (TNBCs), 
representing ~15% of all breast cancers, are 
characterized by the absence of estrogen and 
progesterone receptors and ErbB2, excluding the 
possibility of specific intervention for these tumors. 
They are biologically more aggressive and have a very 
poor outcome compared to other breast tumors [17].  
In this study, we investigated the role of 
PDGFRβ in BM-MSC homing and activity into the 
highly malignant and invasive mesenchymal-like 
(ML) TNBC subtype [17]. We have recently 
demonstrated that cells of this subtype have a strong 
tendency to vasculogenic mimicry (VM) both in vitro 
and in vivo, and that targeting epidermal growth 
factor receptor (EGFR)-integrin αvβ3 interaction by an 
anti-EGFR aptamer, results in inhibition of VM and 
tumor growth in ML TNBC [18].  
To interfere with the PDGFRβ-mediated 
cross-talk between BM-MSCs and tumor cells, we 
used a nuclease-resistant RNA aptamer, named 
Gint4.T, that we have previously characterized as 
high specific inhibitor of the receptor in human 
glioblastoma [19, 20]. The aptamer binds at high 
affinity (Kd: 9.6 nmol/l) to the extracellular domain of 
the PDGFRβ and impedes the ligand-dependent 
activation of the receptor both in vitro and in vivo. 
Further, it has been validated in vivo for its tumor 
targeting efficacy, resulting neither toxic nor 
immunogenic [19, 21]. 
Here we show that Gint4.T aptamer inhibits the 
migration of BM-MSCs towards TNBC cells and their 
trans-differentiation into CAFs. In addition, we used 
in vivo cell-tracking method to monitor instantly, 
noninvasively and in real time the inhibitory effect of 
the aptamer on BM-MSC homing to breast cancer 
xenografts, which ultimately results in interfering 
with BM-MSC-dependent pro-invasive activity. Our 
findings suggest a novel therapeutic agent that blocks 
either the recruitment of BM-MSCs into TME and the 
tumor cell-stroma interactions thus hampering TNBC 
aggressiveness.  
Materials and Methods 
Cell lines and culture condition 
All human breast cancer cell lines came from 
American Type Culture Collection and were grown in 
appropriate medium supplemented with 10% fetal 
bovine serum (FBS), 100 U/ ml penicillin and 100 
μg/ml streptomycin. The cells were maintained in a 
humidified incubator in 5% CO2 at 37 °C. MCF-7 and 
U87MG cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM); MDA-MB-231 and BT-549 
cells were grown in RPMI 1640.  
For production of MDA-MB-231 expressing 
green fluorescent protein (GFP), lentiviral constructs 
and infection of cells were conducted as previously 
described [22]. Briefly, MDA-MB-231 cells were 
plated on 12-well plates and infected with lentiviruses 
in the presence of 10% FBS and 8 μg/ml Polybrene 
(hexadimethrine bromide; Sigma-Aldrich, St. Louis, 
MO). After 48 hours of incubation, infection efficiency 
was determined by analyzing GFP expression by flow 
cytometry. 
To obtain conditioned medium (CM) cells were 
grown in medium with 1% FBS for 48 hours. The 
medium was then collected, centrifuged at 1000 × g 
for 10 minutes, and filtered through 0.22-μm filters 
(Millipore,Billerica, MA) before being used. 
The concentration of PDGF-BB in CM of 
MDA-MB-231 and BT-549 cells was measured using 
the ELISA method as reported [23]. 
Human BM-MSC isolation and culture  
Human BM-MSCs were provided by Dr. 
Lucarelli. Samples were taken from patients after 
obtaining informed consent according to a protocol 
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approved by the Ethics Committee of Rizzoli 
Orthopaedic Institute. Isolation and culture condition 
of human BM-MSC was performed as previously 
described [12]. BM-MSCs immunophenotypic 
characterization was performed by flow cytometry 
using antibodies against CD44, CD73, CD90, CD105, 
CD146 (staminal positive markers) and CD34 and 
CD45 (staminal negative markers). The BM-MSCs 
were used between passages 3-5.  
BM-MSC differentiation into osteoblasts and 
adipocytes has been evaluated as reported [24].  
BM-MSCs grown in the presence of 
MDA-MB-231 CM for 48 hours are referred as 
"BM-MSCMDA-MB 231". 
RNA isolation and Real time-PCR 
RNA isolation and Real time-PCR was 
performed as previously described [12]. Briefly, total 
RNA from BM-MSCs was extracted using TRIzol 
reagent (Invitrogen/Life Technologies, Carlsbad, CA, 
USA) and equal amount of total RNA (200 ng) was 
reverse-transcribed to cDNA using Superscript II 
RNase H-reverse transcriptase according to the 
manufacturer’s instructions (Invitrogen/Life 
Technologies, Carlsbad, CA, USA). Quantitative PCR 
analysis was performed using SYBR Green reaction 
mixture (Bio-Rad, Hercules, CA), and an ABI Prism 
7000 (robocycler was used for amplification Applied 
Biosystems, Carlsbad, CA, USA). The gene-specific 
primers used for the amplifications were as follows: 
PDGFRβ 
5’-AGGACACGCAGGAGGTCAT-3’ (forward) 
5’-TTCTGCCAAAGCATGATGAC-3’ (reverse) 
α-smooth muscle actin (α-SMA) 
5’-ACCCAGCACCATGAAGATCA-3’ (forward) 
5’-AGAGACAGAGAGGAGCAGGA-3’ (reverse) 
Fibroblast-specific Protein 1 (FSP-1) 
5’-CTCTCCTCAGCGCTTCTTCT-3’ (forward) 
5’-GGGTCAGCAGCTCCTTTAGT-3’ (reverse) 
Fibroblast Activation Protein (FAP) 
5’-TACGTTTCATCACTGGCCCT-3’ (forward) 
5’-CATCTGCTGTTCCGTGGATG-3’ (reverse) 
β-actin 
5’-CAAGAGATGGCCACGGCTGCT-3’ (forward) 
5’-TCCTTCTGCATCCTGTCGGCA-3’ (reverse) 
Sox2 
5’-AGAAGGATAAGTACACGCTGC -3’ (forward) 
5’-TCCAGCCGTTCATGTGC -3’ (reverse) 
Nanog 
5’-GAAATACCTCAGCCTCCAGC -3’ (forward) 
5’-GCGTCACACCATTGCTATTC -3’ (reverse) 
Aptamers and treatments 
2′F-Py RNA aptamers (Gint4.T and Scrambled), 
developed by Camorani et al. [19], were synthesized 
by TriLink Biotechnologies and purchased from 
Tebu-bio srl (Magenta, Milan, Italy). Before each 
treatment, the aptamers were subjected to a short 
denaturation-renaturation step as reported [20].  
Gint4.T aptamer, PDGFRβ inhibitor: 
5’-UGUCGUGGGGCAUCGAGUAAAUGCAAUUC
GACA-3’. Aptamer used as a negative control and 
herein indicated as Scr: 5’-UUCGUACCGGGUAGGU
UGGCUUGCACAUAGAACGUGUCA-3’. 
Cell lysate preparation and western blot 
analyses 
Whole-cell lysates and Western blots analyses 
were performed as previously reported [25]. The 
following primary antibodies were used: rabbit 
polyclonal anti-phospho-PDGFRβ (CST-3173, 
indicated as pPDGFRβ), rabbit monoclonal 
anti-PDGFRβ (CST-3169), rabbit polyclonal 
anti-phospho-AKT (CST-9271, indicated as pAKT), 
rabbit polyclonal anti-AKT (CST-9272), rabbit 
polyclonal anti anti-phospho44/42 MAPK (CST-9101, 
indicated as pERK) (Cell Signaling Technology Inc., 
Danvers, MA); rabbit polyclonal anti-α-SMA (ab5694, 
Abcam, Cambridge, MA); mouse monoclonal 
anti-β-actin (A4700, Sigma-Aldrich, St. Louis, MO); 
rabbit polyclonal anti-Erk1 (sc-93) and goat polyclonal 
anti-vinculin (sc-7649) (Santa Cruz Biotechnology, 
Santa Cruz, CA). Detection of the targeted antibody 
was revealed by ECL reagent according to the 
manufacturer’s recommendations. Densitometric 
analyses were performed on at least two different 
expositions to assure the linearity of each acquisition 
using ImageJ software (v1.46r). Blots shown are 
representative of at least three independent 
experiments. 
Cell migration and invasion assays  
Cell migration and cell invasion were performed 
using a 24-well Boyden chambers (Corning, NY) 
containing inserts of polycarbonate membranes with 8 
μm pores [26]. For migration assays, all cells tested 
(0.3 x 105 in 100 μl serum-free medium per well) were 
plated into each upper chamber in the presence of 
different chemoattractants (lower chamber). After 
incubation for 24 hours at 37°C in a humidified 
incubator in 5% CO2, the non-migrating cells were 
removed from the top chamber using a cotton swab, 
and the cells that had migrated to the lower surface of 
 Theranostics 2017, Vol. 7, Issue 13 
 
 
http://www.thno.org 
3598 
the membrane insert were visualized by staining with 
0.1% crystal violet in 25% methanol and counted in 10 
random fields/filter at 200x magnification. Results are 
expressed as the percentage of migrating cells 
considering the untreated control sample as 100%. 
To perform invasion assays, the top 
compartment of Boyden chambers was coated with 50 
μl of diluted (1:3 in PBS) Matrigel (BD Biosciences, 
San Jose, CA). After coating, chambers were 
incubated at 37°C for 1 hour to allow Matrigel to 
solidify. MDA-MB-231 and BT-549 cells (0.5 × 105 in 
100 μl serum-free medium per well) were then added 
to each top chamber. After incubation for 72 hours at 
37°C in a humidified incubator in 5% CO2, invaded 
cells were visualized and analyzed as described 
above. 
Analysis of BM-MSC trans-differentiation into 
CAF  
BM-MSCs and TNBC cells were co-cultured in 
trans-well chambers with microporous-3µm 
membrane (Corning, NY). To this aim, BM-MSCs (1 x 
106 cells) treated or no with Gint4.T and Scr were 
seeded into the lower chamber in a 6-multiwell. After 
incubation for 24 hours at 37°C in a humidified 
incubator in 5% CO2, MDA-MB-231 and BT-549 cells 
(50 x 105 cells) were added to each top chamber. After 
5 days at 37°C in a humidified incubator in 5% CO2, 
total RNA was extracted from BM-MSCs and 
analyzed for CAF markers: α-SMA, FAP and FSP-1.  
NIR fluorescent BM-MSC-labeling 
VivoTrack 680 Fluorescent Cell Labeling Agent 
(MW: 1173 gmol-1; A: 676 nm; Em: 696 nm) was 
commercially obtained from PerkinElmer (Waltham, 
MA), dissolved in 1.3 mL of warm sterile PBS (final 
volume of 2.0 mL). BM-MSCs (1 x 106) were 
re-suspended in 200 µL of sterile PBS and incubated 
with VivoTrack 680 (ratio 1:1, v/v) for 30 minutes at 
37°C under agitation in the dark. Afterwards, the 
suspension was washed three times with PBS 
containing 1% FBS to remove excess cell labeling 
agent. At that time, VivoTrack 680-labeled cell 
viability was assessed microscopically by Tripan-blue 
exclusion (GibcoTM). To verify that the cells were 
successfully labelled, they were examined by flow 
cytometry (BD Accuri™ C6), using appropriate lasers 
and filters for detection of 680 nm wavelength.  
Animal Tumor Models and treatment 
All experimental procedures complied with the 
European Communities Council directives 
(2010/63/EU) and national regulations (D.L. 116/92) 
and were performed in accordance with National 
Institutes of Health (NIH) recommendations. The 
present study was approved by the Italian Ministry of 
Health (authorization number 38/2015-01-28). 
MDA-MB-231 cells (10 × 106) were re-suspended in 0.1 
ml of 1:1 mix of physiological saline and Matrigel and 
subcutaneously injected into the flank of 
five-week-old Female Balb/c nude mice which 
weighed around 18-20 g (Charles River, Milan, Italy). 
Once tumors became palpable (established), 
approximately 50 mm3 [volume = 0.5 × long diameter 
× (short diameter)2], nude mice were randomized into 
2 groups (3 mice for each group) for imaging studies 
[27].  
In order to develop a system that models the 
entire metastatic process, we injected 
MDA-MB-231/GFP cells (1×106) in presence or 
absence of BM-MSCs (1×106) in 150 µl of PBS Matrigel 
mixture (1:1, v:v) orthotopically into the mammary fat 
pads of severely immunocompromised NOD scid 
gamma (NSG) mice. BM-MSCs were treated with 
Gint4.T (1600 pmoles) for 3 hours prior injection. Mice 
(3 mice for each group) were monitored for 
development of primary xenograft tumor with 
high-frequency ultrasound system (Vevo 2100 
equipment; FUJIFILM VisualSonics, Inc., Toronto, 
Ontario, Canada). Sixty days post injection, mice were 
euthanized and tumors and organs were removed. 
They were either stored in 10% neutral buffered 
formalin for paraffin embedding/sectioning and H&E 
staining, or they were embedded in O.C.T. (Optimal 
Cutting Temperature) compound and 10 µm frozen 
sections were incubated with DAPI for 5 minutes to 
stain nuclei blue and subsequently prepared for 
fluorescent microscopy of GFP. 
In vivo tracking of BM-MSC to TNBC 
xenografts by Fluorescence Molecular 
Tomography (FMT) 
For FMT studies, tumor-bearing mice were 
maintained on a diet with a purified, alfalfa-free 
rodent chow for 15 days before fluorescent imaging to 
minimize fluorescence in the gut. VivoTrack 680 alone 
or BM-MSCs (1 × 106) labeled with VivoTrack 680 and 
treated with Gint4.T or the Scr aptamer (1600 pmoles) 
for 3 hours were administered to MDA-MB-231 
xenografts by caudal vein injection. Mice under 
isoflurane anesthesia were analyzed at different time 
points by FMT 4000 imaging system (PerkinElmer, 
Waltham, MA). Epifluorescence (2D) and tomography 
(3D) datasets were both acquired and analyzed by 
FMT system software (TrueQuantTM v4.0) from 
PerkinElmer (Waltham, MA). 3D regions of interest 
(ROIs) were drawn around tumor regions, and a 
threshold was applied equal to 30% of the maximum 
value of fluorescence in the adjoining non-tumor area. 
The total amount (pmoles) of fluorochrome was 
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automatically calculated relative to internal standards 
generated with known concentrations of the 
appropriate dye. After imaging studies, mice were 
euthanized and tumors were excised and then 
harvested for FACS analysis of labeled BM-MSCs. 
Statistical analysis 
Results were obtained from at least three 
independent experiments and are expressed as the 
mean ±SD. Statistical values were defined using 
GraphPad Prism version 6.00 for Windows by t-test. P 
value < 0.05 was considered significant for all 
analyses.  
Results 
BM-MSCs promote TNBC cells migration and 
invasion  
To investigate whether BM-MSCs have the 
ability to promote migration and invasion of ML 
MDA-MB-231 and BT-549 cells a trans-well assay was 
performed, in which each cancer cell line was exposed 
to BM-MSCs, added in the lower chamber (Figure 
1A). We found that TNBC cells migrated much avidly 
when co-cultured with BM-MSCs for 24 hours (Figure 
1B). Similarly, when TNBC cells were seeded on top 
compartment of trans-well coated with Matrigel a 
strong stimulation of their invasion was observed in 
the presence of BM-MSCs (Figure 1C). We also found 
increased expression of stem cell markers, such as 
Sox2 and Nanog in TNBC cells upon BM-MSCs 
co-culture for 5 days (Figure 1D). 
 
 
Figure 1. BM-MSCs augment migration, invasion and stemness of TNBC cells. (A) Representation of BT-549 or MDA-MB-231 cells co-cultured with 
BM-MSCs using Boyden chambers. (B) Migration of BT-549 and MDA-MB-231 cells was analyzed by Boyden chamber containing inserts of polycarbonate membranes 
with 8 μm pores. TNBC cells were seeded into upper chamber and exposed to BM-MSCs grown in medium supplemented with 1% FBS or medium containing 1% FBS 
as a chemoattractant (lower chamber) for 24 hours. (C) Invasion of BT-549 and MDA-MB-231 cells was performed at 72 hours as described above with membranes 
of trans-well coated with Matrigel. Representative photographs of at least three different experiments are shown. The results are expressed as percent of 
migrated/invaded cells and cells vs 1% FBS are reported as 100%. (D) For stemness markers analysis BT-549 and MDA-MB-231 cells were co-cultured with BM-MSCs 
for 5 days using a Boyden chamber containing inserts of polycarbonate membranes with 3 μm pores. Nanog and Sox2 mRNA levels were analyzed by Real Time-PCR. 
All experiments were performed at least three times. *P < 0.01 **P < 0.001 compared to control (medium with 1% FBS). 
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The anti-PDGFRβ aptamer inhibits PDGFRβ- 
mediated signaling pathway in BM-MSCs 
In agreement with previous reports [28], we 
found that BM-MSCs express high levels of PDGFRβ 
protein and mRNA (Figure 2A). Human 
PDGFRβ-positive glioblastoma U87MG and 
PDGFRβ-negative breast cancer MCF-7 cells [19] were 
used as positive and negative control, respectively, in 
western blotting (left panel) and Real Time-PCR (right 
panel) analyses. 
Since several evidences show a critical role for 
PDGFRβ in BM-MSCs homing to tumor sites 
including malignant glioma [29], chronic lymphocytic 
leukemia (CLL) [30] and colon carcinomas [6] we 
wondered whether the Gint4.T RNA aptamer, that we 
previously validated as a specific inhibitor of 
PDGFRβ [19, 20], is able to interfere with this 
phenomenon. The aptamer binds to the extracellular 
domain of human PDGFRβ thus interfering with 
PDGF-BB ligand stimulation of the receptor [19, 20]. 
Firstly, we verified the aptamer ability to inhibit 
ligand-dependent PDGFRβ activation and 
downstream phosphatidyl-3-kinase (PI3K)/AKT and 
extracellular signal-regulated kinase 1/2 (ERK1/2) 
pathways in BM-MSCs upon PDGF-BB stimulation 
(Figure 2B).  
 
 
Figure 2. Gint4.T aptamer inhibits PDGFRβ-mediated downstream signaling pathway in BM-MSCs. (A) Lysates from U87MG, MCF-7 and BM-MSCs 
were analyzed by immunoblot with anti-PDGFRβ antibody, and equal loading was confirmed by immunoblot with anti-actin antibody (left). PDGFRβ mRNA levels 
were analyzed by Real Time-PCR (right). (B) BM-MSCs cells were serum-starved for 18 hours and then left untreated or stimulated for 15 minutes with 100 ng/ml 
PDGF-BB in the absence or in the presence of 200 nmol/l Gint4.T or Scr, as indicated. Cell lysates were immunoblotted with anti-pPDGFRβ, anti-pERK, anti-pAkt 
antibodies. Filters were stripped and reprobed with anti-PDGFRβ, anti-Erk and anti-Akt antibodies, as indicated. Equal loading was confirmed by immunoblot with 
anti-vinculin antibody. The histogram indicates pPDGFRβ/PDGFRβ, pERK/ERK and pAKT/AKT ratio of densitometric signals, reported as relative to Scr-treated cells, 
arbitrarily set to 1. Depicted results represent one of three typical experiments performed. Molecular weights of indicated proteins are reported (A and B). 
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It has been reported that inhibition of PDGFRβ 
and downstream ERK and AKT signaling inhibited 
human MSC osteogenesis in vitro [31]. Accordingly, 
we found that the aptamer hampered BM-MSC 
differentiation into osteoblasts but not into adipocytes 
(Figure S1).  
The anti-PDGFRβ aptamer inhibits BM-MSCs 
migration towards TNBC cells 
Next, we determined whether the 
aptamer-mediated inhibition of intracellular signaling 
initiated by PDGFRβ results in impairment of 
BM-MSCs migration. As shown in Figure 3A, treating 
BM-MSCs with the anti-PDGFRβ aptamer strongly 
reduced cell migration stimulated by serum, causing 
44% inhibition as compared with the Scr aptamer. A 
similar effect was elicited by imatinib mesylate, a 
tyrosine kinase inhibitor acting on different tyrosine 
protein kinases including PDGFRβ [32]. 
MSCs have been recently described to home into 
breast carcinoma in response to numerous endocrine 
and paracrine signals [2, 13, 14]. Importantly, the 
treatment of BM-MSCs with Gint4.T aptamer caused a 
dramatic reduction of their migration toward 
PDGF-BB ligand as compared with controls treatment 
(Mock and Scr) (Figure 3B). Next, we analyzed the 
secretion of PDGF-BB in conditioned medium of 
MDA-MB-231 and BT-549 by ELISA. The data showed 
that PDGF-BB detected in BT-549 was 12,84 ±1.52 
pg/ml whereas in MDA-MB-231 was 6.46 ±1,46 
pg/ml. Accordingly, Gint4.T strongly inhibited 
BM-MSCs migration to both TNBC cell lines (Figure 
3C).  
 
 
 Figure 3. Gint4.T aptamer inhibits BM-MSC migration towards TNBC cells. Migration of BM-MSCs was analyzed by Boyden chamber. (A) BM-MSCs in 
the absence or in the presence of 400 nmol/l Gint4.T, 400 nmol/l Scr or 5µmol/l Imatinib mesylate were placed into upper chamber whereas 10% FBS was used as 
inducer of migration (lower chamber) for 24 hours. (B, C) BM-MSCs in the absence or in the presence of 400 nmol/l Gint4.T or Scr were placed into upper chamber 
whereas 100 ng/ml PDGF-BB (B), MDA-MB-231 (C, upper panels) and BT-549 cells (C, lower panels) were added to the lower chambers. Representative 
photographs of at least three different experiments are shown. The results are expressed as percent of migrated cells and reported as relative to mock-treated cells. 
*P < 0.01,**P < 0.001 compared to mock-treated cells; #P < 0.01, ##P < 0.001 compared to Scr aptamer. 
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These results indicate that inhibiting PDGFRβ 
with Gint4.T hampers the homing of BM-MSCs to 
TNBC cell lines. 
The anti-PDGFRβ aptamer inhibits BM-MSC 
trans-differentiation into Cancer Associated 
Fibroblasts  
Because CAFs are well known to play a key role 
in tumor progression and metastatic spread we 
wondered whether BM-MSCs when co-cultured with 
TNBC cells acquire the expression of CAF-specific 
markers. Interestingly, a significant increase of mRNA 
levels of α-SMA, FAP and FSP-1 was observed when 
BM-MSCs were exposed up to 5 days to MDA-MB-231 
and BT-549 cells, thus indicating that TNBC are able 
to induce BM-MSCs trans-differentiation into 
CAF-like cells (Figure 4A). Importantly, Gint4.T 
treatment strongly reduced CAF markers mRNA 
expression in BM-MSCs, co-cultured with 
MDA-MB-231 (Figure 4B, left) and BT-549 (Figure 4B, 
right) compared to Scr negative control, thus 
suggesting the aptamer ability to prevent BM-MSC 
differentiation into CAFs in TNBC microenvironment. 
Further, in order to assess the effect of the aptamer on 
the pro-invasive function of CAF-like BM-MSCs, 
BM-MSCs were grown for 48 hours in the presence of 
CM from MDA-MB-231 (BM-MSCMDA-MB 231) to induce 
a CAF-like phenotype (Figure 4C). Next, 
MDA-MB-231 cells invasiveness was assessed by 
using CM from naïve BM-MSCs and from 
BM-MSCMDA-MB-231 as chemoattractant in the transwell 
invasion assay. As shown (Figure 4D), CM from 
BM-MSCMDA-MB-231 strongly increased the invasion 
rate of MDA-MB-231 cells compared to CM from 
naïve BM-MSCs and, importantly, Gint4.T interfered 
with this event.  
These results indicate that blocking PDGFRβ on 
BM-MSCs with Gint4.T aptamer not only decreased 
their ability to migrate towards TNBC cells but also 
their capability to trans-differentiate in CAFs and to 
induce a pro-invasive phenotype of TNBC cells.
 
 
Figure 4. Gint4.T inhibits BM-MSC trans-differentiation into Cancer Associated Fibroblasts. (A) BM-MSCs were co-cultured with MDA-MB 231 or BT-549 cells 
for 5 days using a Boyden chamber containing inserts of polycarbonate membranes with 3 μm pores. α-SMA, FAP and FSP-1 mRNA levels were detected using Real Time-PCR. 
*P < 0.01,**P < 0.001 compared to BM-MSCs. (B) BM-MSCs incubated with 400 nmol/l Gint4.T or Scr were co-cultured with MDA-MB 231 or BT-549 cells as described above. 
α-SMA, FAP and FSP-1 mRNA levels were quantified using Real Time-PCR and reported as relative to Scr-treated cells, used as negative control. #P < 0.01, ##P < 0.001 
compared to Scr aptamer. (C) Lysates from BM-MSCs grown for 48 hours in medium supplemented with 1% FBS or in CM from MDA-MB-231 (BM-MSCMDA-MB 231) in the absence 
or in the presence of 400 nmol/l Gint4.T, were immunoblotted with anti-α-SMA and anti-vinculin antibodies. Values below the blot indicate signal levels relative to BM-MSCs 
grown in 1% FBS medium, arbitrarily set to 1 (labeled with asterisk). Molecular weights of indicated proteins are reported. (D) MDA-MB-231 cells were placed into upper 
matrigel-coated compartment of Boyden chamber and exposed to conditioned media from BM-MSCs grown as in (C) as chemoattractants (lower chamber) for 24 hours. 
Representative photographs of at least three different experiments are shown. The results are expressed as percent of invaded cells and reported as relative to BM-MSC CM.  
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The anti-PDGFRβ aptamer inhibits BM-MSC 
recruitment into TNBC xenografts as assessed 
by Fluorescence Molecular Tomography 
To follow the homing of BM-MSCs toward 
TNBC in vivo, we labeled the cells with VivoTrack 680 
Fluorescent Cell Labeling Agent. As assessed by flow 
cytometry analysis, a total labeling efficiency was 
obtained at the experimental condition used (Figure 
5A). First, we checked the absence of cell viability loss 
after labeling (data not shown). Then, nude mice 
bearing MDA-MB-231 xenografts, were intravenously 
injected with VivoTrack 680-labeled BM-MSCs, 
treated with Gint4.T or the Scr aptamer, and analyzed 
by Fluorescence Molecular Tomography at different 
time-points (Figure 5B). 3D images were 
reconstructed and volumes of interest (VOIs) were 
generated around the tumor. The fluorescence signal 
of BM-MSCs was visualized in the tumor at 2 hours 
post-injection and remained visualized up to 24 hours 
(Figure 5C). Because VivoTrack 680 emits at NIR 
wavelength where autofluorescence and tissue 
absorbance are minimal, a low fluorescence was 
observed in the tissues around the tumor. As shown, 
the treatment of BM-MSCs with Gint4.T aptamer 
strongly reduced BM-MSC recruitment into 
MDA-MB-231 xenografts compared to the negative 
control (Figure 5C). Moreover, FACS analysis of NIR 
labeled BM-MSCs in cell suspension from tumors, 
revealed a significant decrease of BM-MSCs 
recruitment in tumors after their treatment with 
Gint4.T aptamer (Figure 5D), thus confirming the 
results of in vivo imaging. These findings prove the 
ability of the aptamer to inhibit tropism of BM-MSCs 
to TNBC targeting PDGFRβ.  
 
 
Figure 5. Representative images of BM-MSC recruitment into TNBC xenografts by fluorescence tomography and BM-MSCs pro-metastatic 
activity. (A) BM-MSCs were incubated with VivoTrack 680 for 30 minutes and the dye uptake was analyzed by flow cytometry. (B-C) Nude mice bearing 
MDA-MB-231 xenografts were i.v. injected with VivoTrack 680-labeled BM-MSCs treated with Gint4.T or Scr aptamer and analyzed with FMT. (D) FACS analysis of 
NIR labeled BM-MSCs in cell suspension from tumors (#P < 0.01, compared to Scr aptamer). (E) Representative fluorescence (upper panels) and H&E (lower panels) 
images of lung sections from mice injected with MDA-MB-231/GFP cells alone or mixed with BM-MSCs, left untreated or treated with Gint4.T for 3 hours prior to 
injection. Multifocal metastatic lesions expressing GFP or H&E-stained are indicated by white and black arrows, respectively. Nuclei were stained with DAPI. All 
images had a magnification of 5.41x from the initial slide scan. Scale bar = 100 μm. Metastatic foci in lung sections were counted on at least 5 random fields per section 
(n = 3 mice, *P < 0.01 compared to MDA-MB-231/GFP; #P < 0.01 compared to MDA-MB-231/GFP +BM-MSCs). 
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The anti-PDGFRβ aptamer inhibits BM-MSC 
induced TNBC metastasis in vivo 
In agreement with previous report [2] we found 
that the growth of MDA-MB-231 cells is not affected 
when breast cancer cells were co-injected with 
BM-MSCs in mammary fat pad of 
immunocompromised mice (Figure S2). Conversely, 
BM-MSCs increased the metastatic potential of 
MDA-MB-231 cells in orthotopic model [2] thus 
correlating with our in vitro findings. To investigate 
whether the anti-PDGFRβ aptamer has the ability to 
inhibit BM-MSC induced TNBC metastasis in vivo, 
GFP-labelled MDA-MB-231 were mixed with 
BM-MSCs, left untreated or prior treated with 
Gint4.T, and injected in mammary fat pad of mice. 
After 8 weeks, mice were sacrificed and the lungs 
were extracted for analysis. Although no visible 
macro-metastatic lesions were observed in each 
experimental mouse group, GFP fluorescence was 
evident in the lung sections demonstrating 
microscopic metastasis. As shown (Figure 5E), 
BM-MSCs induced a significant enhancement in the 
number of detectable multifocal metastatic lesions 
that was counteracted by Gint4.T treatment. 
Discussion 
Since the tumor microenvironment contributes 
to many aspects of carcinogenesis and cancer 
progression, the different stromal cell types, which 
play key roles in determining or enhancing several 
hallmark capabilities in different TMEs, should be 
taken into account to stimulate future anticancer drug 
development. In particular, the recent discovery that 
MSCs can be recruited into TME and promote cancer 
progression has led to consider MSCs as a suitable 
target for anti-cancer therapy. Importantly, tumor 
associated-MSCs contribute to tumor cell growth and 
metastatic behavior in a variety of cancers, including 
breast [2], prostate [5, 33], osteosarcoma [12, 26, 34] 
and colon [6] cancers. The high tropism of MSCs for 
malignant tumors is largely similar to what observed 
for inflamed and injured tissues and involve the same 
growth factors, chemokines and cytokines [8]. Tumor 
cells are able to produce a chemotactic gradient 
consisting of different chemokines such as CCL2, 
CCL5, CXCL12 and CXCL16, which is able to recruit 
MSCs [35].Jung et al. (2013) showed that MSCs were 
both recruited as well as transformed in CAFs by 
CXCL16 produced by prostate cancer cells. In turn, 
MSC-like CAFs secreted CXCL12 that binding to 
CXCR4 on tumor cells induced an EMT, which 
ultimately promoted metastasis to secondary tumor 
sites [5].  
Many growth factors such as PDGF, vascular 
endothelial growth factor (VEGF), insulin-like growth 
factor 1 (IGF-1), TGF-β and basic fibroblast growth 
factor (bFGF) have been found to effectively mediate 
MSC homing to TME [36].Interestingly, several 
studies reported PDGF-BB as a critical mediator of 
MSC tropism to gliomas [37-39]. It has been reported 
that recruitment of MSCs towards pancreatic tumors 
in response to PDGF, EGF and VEGF, can be inhibited 
by Glivec, Erbitux and Avastin, respectively [40]. 
Furthermore, it has been demonstrated that bFGF and 
downstream ERK/Smad3 signaling pathway are 
involved in BM-MSC tropism to 4T1 breast cancer 
cells by using a specific neutralizing antibody [41]. 
 An increasing number of evidence has shown 
that MSCs in primary tumors can differentiate in 
active components of the tumor microenvironment 
such as CAFs, which are known to play a key role in 
tumor progression [42], neo-angiogenesis [43], EMT 
[44] and metastatic spread [45]. Therefore, great 
interest has been shown in developing therapeutic 
targeting strategies aimed to inhibit MCS support 
thus improving therapeutic efficacy in treating cancer 
[46, 47]. Thus, in this scenario, the starting point for 
MSC targeted therapy is the identification of specific 
molecular pathways involved in pro-tumorigenic 
cross-talk between MSCs and cancer cells. The 
delineation of key molecular pathways that underlie 
this important interplay has improved the knowledge 
of the biology of TME, tumor spreading, and 
carcinogenesis. Over past years, several studies have 
shown that MSCs express high levels of PDGFRβ [28] 
suggesting that it could play a crucial role in processes 
in which MSCs are involved. In fact, it is widely 
reported that PDGFRβ is involved in specifying MSC 
commitment to mesenchymal lineages as well as in 
MSC proliferation and self-renewal [48]. Furthermore, 
PDGFRβ signaling has emerged as a predominant 
pathway in recruitment of MSCs towards tumor sites 
[15]. Hata et al. [29], for example, have demonstrated 
that PDGFRβ is involved in MSC tropism for 
malignant gliomas, providing direct evidence that 
tumor is capable of attracting MSCs in an intracranial 
glioma model through PDGFRβ pathway. 
Furthermore, it has been reported that 
PDGFRβ-mediated MSC recruitment into TME, 
contributed to enhance the aggressive and invasive 
properties of many other tumors, including chronic 
lymphocytic leukemia [30] and colon carcinomas [6]. 
However, although PDGFRβ inhibitors have already 
been tested for their capability to target and interfere 
with receptor activity in MSCs, no studies have still 
demonstrated the possibility to target PDGFRβ to 
prevent pro-tumorigenic effect of MSCs into tumor 
microenvironment. Moreover, the current class of 
PDGFRβ drugs consists of small molecule TKIs that 
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show limited specificity and modest efficacy whereas 
no antibodies have entered the clinic. This study 
reports, for the first time, an innovative therapeutic 
tool, an anti-PDGFRβ aptamer [19, 20] able to prevent 
BM-MSC recruitment and activity into TNBC 
microenvironment. Recent evidences have widely 
shown that BM-MSCs can integrate into the 
tumor-associated stroma and promote the 
progression of TNBC through the activation of 
different mechanisms involving HIFs [14], TGF-β [13] 
and CCL5 [2]. Up to now, no work has demonstrated 
the involvement of PDGFRβ pathway in MSC homing 
toward TNBC microenvironment, as well as 
MSC-mediated TNBC progression. Interestingly, in 
this study we show that the anti-PDGFRβ aptamer 
strongly reduces both in vitro BM-MSC migration 
stimulated by two different TNBC cell lines and in 
vivo BM-MSC recruitment into TNBC xenografts, as 
assessed by FMT. These results underline the 
importance of PDGFRβ in mediating MSC migration 
towards TNBC site and highlights Gint4.T aptamer to 
specifically prevent PDGFRβ-mediated MSC tropism 
for TME. Finally, recent evidence has demonstrated 
that MSCs selectively proliferate in TME and 
trans-differentiate in pro-tumor supporting CAFs 
[10]. Although the effect of MSCs on growth of breast 
cancer is controversial and probably depends on the 
experimental setting of the animal model [49], 
conversely, it is well established that MSCs have a 
significant impact on promoting breast cancer 
metastasis [50]. Our data demonstrated that Gint4.T 
aptamer not only hampers PDGFRβ downstream 
signaling in BM-MSCs, but it also interferes with their 
recruitment into TNBC and with their differentiation 
into CAF thus preventing metastatic lung lesions 
(Figure 6).  
Conclusions 
Tumor microenvironment recruits MSCs from 
the circulation, adjacent tissues and bone-marrow 
thus educating these cells to adopt pro-tumorigenic 
phenotypes. MSCs in tumor cause a formation of an 
immunosuppressive microenvironment and can also 
enhance the proportions of cancer stem cells, promote 
EMT, and stimulate tumor angiogenesis. These effects 
contribute to tumor growth, progression, and 
metastasis. Our aptamer-based approach to interrupt 
the cross-talk between cancer cells, MSCs and the 
inflammatory tumor microenvironment will likely 
provide new anti-cancer opportunities. 
 
 
Figure 6. Schematic illustration of Gint4.T effect on recruitment and activity of BM-MSCs into triple negative breast cancer 
microenvironment. Gint4.T targeting PDGFRβ inhibits BM-MSCs homing to cancer cells and their trans-differentiation into cancer associated fibroblasts (CAFs) 
as well as BM-MSC pro-metastatic function. 
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